Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of LB-P6 or LB-P8 in Healthy Participants
NCT05053165Phase 1Completed
- Sponsor
- LISCure Biosciences
- Start
- Jan 2022
- Primary completion
- Apr 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) and Nonalcoholic steatohepatitis (NASH) comparing LB-P6, LB-P8 and Placebo (3 arms). Primary endpoint: Incidence of Adverse Events. Started Jan 2022; status: completed.
02
Drugs
LB-P6LB-P8
03
Conditions
rheumatoid arthritis (RA)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05053165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053165.